Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Depemokimab - GSK

Next Previous
Search
Drug Profile

Depemokimab - GSK

Alternative Names: AQ82742999; GSK 294; GSK-3511294

Latest Information Update: 24 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Asthma; Rhinosinusitis
  • Phase III Churg-Strauss syndrome; Hypereosinophilic syndrome

Most Recent Events

  • 28 Jan 2025 Preregistration for Asthma (Adjunctive treatment, In adolescents, In children, In the elderly, In adults) in European Union (SC)
  • 28 Jan 2025 Preregistration for Rhinosinusitis (Adjunctive treatment, Treatment-experienced) in European Union (SC) (9436515)
  • 28 Jan 2025 The EMA accepts MAA for depemokimab for Asthma and Rhinosinusitis for review (9436515 )

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top